Scribe Therapeutics Inc. (SCTX:NASDAQ) closed at $20.08 on October 16, 2026, down 3.09% on the day. The stock trades 49.3% below its 52-week high of $39.60 and 48.7% above its 52-week low of $13.50. Over the past year, it lost 7.3%. Scribe Therapeutics Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -2.85% | -37.52% | -7.25% | -7.25% | -7.25% |
In 59 trading sessions since July 27, 2026, SCTX closed higher on 31 days (53%). Its best day was August 18, 2026 (+27.94%) and its worst was September 30, 2026 (-20.06%). The stock moved 10% or more in a single session 11 times.
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design¿ approach and nature's blueprint for improved cardiovascular health, Scribe's initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company's lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly.
Find more stocks like SCTX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.